Obermatt
See Similar Stocks →

Apogee Therapeutics

NMQ:APGE · US03770N1019
BiotechnologySmall

360

58
Medium confidence — indicative
Profit price74
Cash yield1
Price/Sales15
Price/Book26
Return on Capital40
Cash Return on Capital53
Return on Equity52
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth16
Long-Term EPS Growth80
Reinvestment34
Price momentum78
Debt load90
Refinancing89
Debt Payback1
Liquidity12
Analyst ratings31
Opinion Changes69
Price Target Upside40
Market mood76
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Apogee Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2022
Employees276
Websiteapogeetherapeutics.com
ISINUS03770N1019
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesInflammationAllergyImmunologyPulmonologyDermatologyRespiratoryBiotechnologyLife ScienceMedicalTherapeutics

Description

Apogee Therapeutics, Inc. (Apogee) operates as a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (‘I&I’) markets, including…

Analysis

Middle-of-the-road

Apogee Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 5/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
91
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
15
—
—
—
Price/Earnings
92
—
—
—
Price/Book
26
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
69
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Apogee Therapeutics with its peers
Eupraxia Pharmaceuticals
TOR:EPRX
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Connect Biopharma Holdings
NMQ:CNTB
55
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →